[68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT在初诊胃癌原发灶及腹膜转移 delineation 上优于[18F]FDG PET/CT
回顾性比较61例初诊胃癌患者的[68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT与[18F]FDG PET/CT,前者原发灶SUVmax更高(14.60 vs 4.35,p<0.001)、阳性检出率更高(95.1% vs 73.8%,p<0.001),印戒细胞癌亚组为96.4% vs 57.1%(p<0.001);腹膜转移灵敏度更高(92.3% vs 53.8%,p=0.002);但两种方法均低估N分期。
要点
- FAPI PET/CT对胃癌原发灶检出率95.1%,高于FDG的73.8%,印戒细胞癌亚组差异更明显(96.4% vs 57.1%)。
- FAPI PET/CT对腹膜转移灵敏度92.3%,高于FDG的53.8%,腹膜癌指数评分18 vs 3。
- 两种方法均低估N分期,FAPI检出阳性淋巴结637枚 vs FDG 407枚。
核心结论
- 在初诊胃癌中,[68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT在原发灶(尤其印戒细胞癌)和腹膜转移评估上优于[18F]FDG PET/CT,但N分期无临床有用的改善。
研究设计与样本
- 回顾性研究,纳入2020年9月至2021年3月61例初诊胃癌患者(男37例,年龄23-81岁),其中22例行根治性胃切除术;比较[68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT与[18F]FDG PET/CT,以病理为参考标准。
诊断标准与关键数值
- 原发灶阳性检出率FAPI 95.1% vs FDG 73.8%(p<0.001),印戒细胞癌亚组FAPI 96.4% vs FDG 57.1%(p<0.001);腹膜转移灵敏度FAPI 92.3% vs FDG 53.8%(p=0.002);原发灶中位SUVmax FAPI 14.60 vs FDG 4.35(p<0.001);腹膜癌指数评分FAPI 18 vs FDG 3(p<0.001);阳性淋巴结FAPI 637枚 vs FDG 407枚。
临床应用与阅片要点
- 作者认为[68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT在初诊胃癌原发灶(尤其印戒细胞癌)和腹膜转移评估上优于[18F]FDG PET/CT;但N分期无临床有用的改善,两种方法均低估N分期。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aimed to compare [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT with [18F]FDG PET/CT in the evaluation of initial gastric cancer.
METHODS: We retrospectively compared [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT with [18F]FDG PET/CT in patients with initial gastric cancer from September 2020 to March 2021. Lesion detectability and the uptake of lesions quantified by the maximum standardized uptake value (SUVmax) and target-to-background ratio (TBR) were compared between the two modalities using the Wilcoxon signed-rank test, Mann-Whitney U test, and McNemar's chi-square test.
RESULTS: A total of 61 patients (37 males, aged 23-81 years) were included, of which 22 underwent radical gastrectomy. For primary lesions, higher uptake of [68Ga]Ga-FAPI-04/[18F]FAPI-42 was observed compared to [18F]FDG (median SUVmax, 14.60 vs 4.35, p < 0.001), resulting in higher positive detection using [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT than [18F]FDG PET/CT (95.1% vs 73.8%, p < 0.001), particularly for tumors with signet-ring cell carcinoma (SRCC) (96.4% vs 57.1%, p < 0.001). [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT detected more positive lymph nodes than [18F]FDG PET/CT (637 vs 407). However, both modalities underestimated N staging compared to pathological N staging. [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT showed a higher sensitivity (92.3% vs 53.8%, p = 0.002) and peritoneal cancer index score (18 vs 3, p < 0.001) in peritoneum metastasis and other suspect metastases compared to [18F]FDG PET/CT.
CONCLUSION: Our findings indicate that [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT outperformed [18F]FDG PET/CT in the evaluation of primary tumors with SRCC and peritoneum metastasis in initial gastric cancer. However, no clinically useful improvement was seen in N staging.
KEY POINTS: • The uptake of [68Ga]Ga-FAPI-04/[18F]FAPI-42 in primary tumor and metastasis was intensely higher than that of [18F]FDG (p < 0.001) in 61 patients with initial gastric cancer. • [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT had a higher sensitivity detection in primary tumors (95.1% vs 73.8%, p < 0.001) and peritoneal metastases (92.3% vs 53.8%, p = 0.002) than [18F]FDG PET/CT. • [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT depicted more positive lymph nodes than [18F]FDG PET/CT (637 vs 407); however, both underestimated N staging compared to pathological N staging.
引用
- Fu, Huang, Wu, et al. Superiority of [68Ga]Ga-FAPI-04/[18F]FAPI-42 PET/CT to [18F]FDG PET/CT in delineating the primary tumor and peritoneal metastasis in initial gastric cancer. Eur Radiol. 2022. PMID: 35380229. doi:10.1007/s00330-022-08743-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。